National Cancer Institute
Central IRB Initiative

COI Screening For *Month, Day, Year* Meeting

OMB #0925-xxxx Expiry Date: xx/xx/xxxx

Collection of this information is authorized by The Public Health Service Act, Section 411 (42 USC 285a). Rights of your participation in the NCI CIRB is protected by The Privacy Act of 1974. Participation is voluntary, and there are no penalties for not participating or withdrawing from the NCI CIRB at any time. Refusal to participate will not affect your benefits in any way. The information collected will be kept private to the extent provided by law. Names and other identifiers will not appear in any report of the NCI CIRB. Information provided will be combined for all participants an reported as summaries. You are being requested to complete this instrument so that we can conduct activities involved with the operations of NCI CIRB Initiative.

NOTIFICATION TO RESPONDENT OF ESTIMATED BURDEN

Public reporting burden for this collection of information is estimated to average 15 minutes per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing the collection of information. **An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB control number.** Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden, to: NIH, Project Clearance Branch, 6705 Rockledge Drive, MSC 7974, Bethesda, MD 20892-7974, ATTN: PRA (0925-0625*). Do not return the completed form to this address.

1. Initial Reviews

Study ID*, *Study Title (Protocol Version Date MM/DD/YY)

Study Chair: *Name; Institution*

Agent / Drug / Enterprise
Agent – Manufacturer (Supplier)

Check the box next to the statement if the statement is true of you, an immediate family[1] member or a person in a direct supervisory or reporting relationship with you. A checked box indicates you are conflicted for review of the study. Report the conflict to the CIRB Operations Office in advance of the CIRB Meeting.

	You	**Family Member**	**Supervisor/ Employee**
Have a role in the oversight, design or conduct of the project or has a role in the analysis or management of the data (this includes: ☐ sitting on a governing body or significant supervisory committee of the Coordinating Group, ☐ serving as a Study Chair for any study of the Coordinating Group, or ☐ working at the same institution as the Study Chair	☐	☐	☐
Have a financial interest of $5000 or more in any agent/device/enterprise involved in the study, or any direct competitor (does not apply if the investment is not under your direct control, i.e. investment via a mutual fund)	☐	☐	☐
Have received any compensation within the last two years from any enterprise involved in the study, or any direct competitor	☐	☐	☐

[1] "Immediate Family" is defined by the CIRB SOPs as a spouse, significant other or dependent child.

	Have a proprietary interest in the research such as a licensing agreement, copyright, patent, or trademark	☐	☐	☐
	Have the potential to gain academic or career advancement based upon participation in the study	☐	☐	☐
	Have an interest (financial or non-financial) that the CIRB or the CIRB member believes conflicts with or biases his/her ability to objectively review the study	☐	☐	☐

2. OtherReviews

Study ID*, *Study Title (Protocol Version Date MM/DD/YY) **Study Chair:** *Name; Institution* **Agent / Drug / Enterprise** *Agent – Manufacturer (Supplier*)	**Check the box next to the statement if the statement is true of you, an immediate family member or a person in a direct supervisory or reporting relationship with you. A checked box indicates you are conflicted for review of the study. Report the conflict to the CIRB Operations Office in advance of the CIRB Meeting.**			
	Are a Coordinating Group investigator for this study AND have done any of the following: ☐ enrolled a participant, ☐ identified a prospective participant (i.e. actively evaluating a patient for potential participation in the study) ☐ performed any directed research-related interventions and interactions with a participant on this study (this does not apply to cross-over attending)	**You** ☐	**Family Member** ☐	**Supervisor/ Employee** ☐
	Have a role in the oversight, design or conduct of the project or has a role in the analysis or management of the data (this includes: ☐ sitting on a governing body or significant supervisory committee of the Coordinating Group, ☐ serving as a Study Chair for any study of the Coordinating Group, or ☐ working at the same institution as the Study Chair	☐	☐	☐
	Have a financial interest of $5000 or more in any agent/device/enterprise involved in the study, or any direct competitor (does not apply if the investment is not under your direct control, i.e. investment via a mutual fund)	☐	☐	☐

	Have received any compensation within the last two years from any enterprise involved in the study, or any direct competitor	☐	☐	☐
	Have a proprietary interest in the research such as a licensing agreement, copyright, patent, or trademark	☐	☐	☐
	Have the potential to gain academic or career advancement based upon participation in the study	☐	☐	☐
	Have an interest (financial or non-financial) that the CIRB or the CIRB member believes conflicts with or biases his/her ability to objectively review the study	☐	☐	☐